Addiction

Papers
(The H4-Index of Addiction is 37. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Issue Information159
Commentary on Borodovsky et al.: Enhancing research on THC quantification—Consumer awareness through accurate labelling152
An Addiction series on regional perspectives on addiction‐related problems137
92
88
Society for the Study of Addiction Annual Conference 202484
Nicotine strength of e‐liquids used by adult vapers in Great Britain: A population survey 2016 to 202483
Impulsivity behaviors and white matter mediate the relationship between genetic risk for cannabis use disorder and early cannabis use in adolescents72
Commentary on Keyes and Patrick: Changes in psychedelic use in the United States may require changes in our narrative of psychedelic harms70
National profile on substance use, substance use‐related problems and policy: The case of Chile70
Does recreational cannabis legalization change cannabis use patterns? Evidence from secondary school students in Uruguay68
Rare but relevant series66
The use of financial incentives for smoking cessation in pregnant women: A parallel‐group randomised controlled trial protocol65
Recent decline in Chinese alcohol production and consumption: Potential contributing factors and the role of globally recommended measures64
Commentary on Stull et al.: Considering person‐specific heterogeneity when modeling time‐varying trends64
Austin Bradford Hill’s ‘Environment and disease: Association or causation’62
Cost‐effectiveness of integrated treatment for hepatitis C virus (HCV) among people who inject drugs in Norway: An economic evaluation of the INTRO‐HCV trial59
Will Australia's tightened prescription system reduce nicotine vaping among young people?58
Education matters: longitudinal pathways to mid‐life heavy drinking in a national cohort of black Americans56
Commentary on Nower et al: The Pathways Model should apply to non‐clinical gambling patterns56
Cannabis: Global Histories by Lucas Richert and James H. Mills, editors54
How substance use prevention research gets used in United States federal policy52
Did the under‐reporting of meth/amphetamine use increase in a general population survey in Australia as negative media coverage increased?46
Naloxone administration—no balance without titration46
Quantifying alcohol‐attributable disability‐adjusted life years to others than the drinker in Aotearoa/New Zealand: A modelling study based on administrative data45
Response to Hall et al.: Prescription psychostimulants for amphetamine‐type stimulant use disorder ‐ acknowledging challenges but not giving up on its potential cost‐effectiveness45
Risk of readmission among individuals with cannabis use disorder during a 15‐year cohort study: the impact of socio‐economic factors and psychiatric comorbidity43
Technology‐mediated just‐in‐time adaptive interventions (JITAIs) to reduce harmful substance use: a systematic review42
Association of topiramate prescribed for any indication with reduced alcohol consumption in electronic health record data42
Opioid overdose deaths and the expansion of opioid agonist treatment: a population‐based prospective cohort study41
ABC‐training as a new intervention for hazardous alcohol drinking: Two proof‐of‐principle randomized pilot studies41
Safety of ibogaine administration in detoxification of opioid‐dependent individuals: a descriptive open‐label observational study41
Predictors of substance use during treatment for addiction: A network analysis of ecological momentary assessment data41
Preventing Overdose Using Information and Data from the Environment (PROVIDENT): protocol for a randomized, population‐based, community intervention trial40
Significant changes in preference of illicit drug use in a population of Hanoi, Vietnam—A 6‐year wastewater study (2018–2023)40
Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial39
Systematic review and meta‐analyses of cytisine to support tobacco cessation37
0.06374192237854